{
  "source": "PA-Med-Nec-Taltz.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2104-19\nProgram Prior Authorization/Medical Necessity\nMedication Taltz (ixekizumab)*\n* Taltz is excluded from coverage for the majority of our benefits\nP&T Approval Date 8/2016, 5/2017, 2/2018, 2/2019, 9/2019, 5/2020, 7/2020, 11/2020,\n6/2021, 12/2021, 3/2022, 6/2022, 11/2022, 1/2023, 4/2023, 7/2023,\n10/2024, 4/2025\nEffective Date 6/1/2025\n1. Background:\nTaltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of\nmoderate to severe plaque psoriasis in patients aged 6 years or older who are candidates for\nsystemic therapy or phototherapy. It is also indicated for the treatment of adult patients with\nactive psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of\ninflammation, or active ankylosing spondylitis.1\n2. Coverage Criteriaa:\nA. Plaque Psoriasis (PsO)\na. Taltz will be approved based on all of the following criteria:\n(1) Submission of medical records (e.g., chart notes, laboratory values) documenting\nall of the following:\n(a) One of the following:\ni. All of the following:\na. Diagnosis of chronic moderate to severe plaque psoriasis\n-AND-\nb. One of the following:\n1. All of the following:\na.) Greater than or equal to 3 % body surface area involvement,\npalmoplantar, facial, genital involvement, or severe scalp\npsoriasis\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\nb.) History of failure to one of the following topical therapies,\nunless contraindicated or clinically significant adverse\neffects are experienced (document drug, date, and duration\nof trial):\n• Corticosteroids (e.g., betamethasone, clobetasol,\ndesonide)\n• Vitamin D analogs (e.g., calcitriol, calcipotriene)\n• Tazarotene\n• Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\n• Anthralin\n• Coal tar\n-AND-\nc.) History of failure to a 3 month trial of methotrexate at\nmaximally indicated dose, unless contraindicated or\nclinically significant adverse effects are experi",
    "rolimus)\n• Anthralin\n• Coal tar\n-AND-\nc.) History of failure to a 3 month trial of methotrexate at\nmaximally indicated dose, unless contraindicated or\nclinically significant adverse effects are experienced\n(document date and duration of trial)b\n-OR-\n2. Patient has been previously treated with a targeted\nimmunomodulator FDA-approved for the treatment of plaque\npsoriasis as documented by claims history or submission of\nmedical records (Document drug, date, and duration of therapy)\n[e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast),\nSkyrizi (risankizumab-rzaa), ustekinumab, Tremfya\n(guselkumab), Enbrel (etanercept)].\n-AND-\nc. History of failure, contraindication, or intolerance to three of the\nfollowing preferred products (document drug, date, and duration of\ntrial):\n• One of the preferred adalimumab productsc\n• Cimzia (certolizumab)\n• Cosentyx (secukinumab)\n• Enbrel (etanercept)\n• Skyrizi (risankizumab)\n• Sotyktu (deucravacitinib)\n• One of the preferred ustekinumab productsc\n• Tremfya (guselkumab)\n-OR-\nii. All of the following:\n© 2025 UnitedHealthcare Services Inc.\n2\na. Diagnosis of chronic moderate to severe plaque psoriasis\n-AND-\nb. Patient is less than 18 years of age\n-AND-\nc. History of failure, contraindication, or intolerance to Cosentyx\n(secukinumab), Enbrel (etanercept), or one of the preferred\nustekinumab productsc(document date and duration of trial)\n-AND-\n(b) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nSiliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Sotyktu (deucravacitinib), Otezla\n(apremilast)]\n-AND-\n(c) Prescribed by or in consultation with a dermatologist\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\na. Taltz will be approved b",
    "cravacitinib), Otezla\n(apremilast)]\n-AND-\n(c) Prescribed by or in consultation with a dermatologist\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\na. Taltz will be approved based on the following criteria:\n(1) Submission of medical records (e.g., chart notes, laboratory values) documenting\nall of the following:\n(a) Diagnosis of active psoriatic arthritis\n-AND-\n(b) One of the following:\ni. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\nii. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of psoriatic arthritis as documented by\nclaims history or submission of medical records (Document drug, date,\n© 2025 UnitedHealthcare Services Inc.\n3\nand duration of therapy) [e.g., Cimzia (certolizumab), Cosentyx\n(secukinumab), adalimumab, Simponi (golimumab), ustekinumab,\nTremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla\n(apremilast), Skyrizi (risankizumab), Rinvoq (upadacitinib), Enbrel\n(etanercept)]\n-AND-\n(c) History of failure, contraindication, or intolerance to three of the following\npreferred products (document drug, date, and duration of trial):\ni. One of the preferred adalimumab productsc\nii. Cimzia (certolizumab)\niii. Cosentyx (secukinumab)\niv. Enbrel (etanercept)\nv. Simponi (golimumab)\nvi. Skyrizi (risankizumab)\nvii. One of the preferred ustekinumab productsc\nviii. Tremfya (guselkumab)\n-AND-\n(d) History of failure, contraindication, or intolerance to one of the following\n(document drug, date, and duration of trial):\ni. Orencia (abatacept)\nii. Xeljanz/Xeljanz XR (tofacitinib)\niii. Rinvoq (upadacitinib)\n-AND-\n(e) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi\n(risankiz",
    "iving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n-AND-\n(f) Prescribed by or in consultation with one of the following:\ni. Rheumatologist\nii. Dermatologist\nAuthorization will be issued for 12 months.\nC. Ankylosing Spondylitis (AS)\na. Taltz will be approved based on the following criteria:\n© 2025 UnitedHealthcare Services Inc.\n4\n(1) Submission of medical records (e.g., chart notes, laboratory values) documenting\nall of the following:\n(a) Diagnosis of active ankylosing spondylitis\n-AND-\n(b) One of the following:\ni. History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date,\nand duration of trials)\n-OR-\nii. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of ankylosing spondylitis as documented\nby claims history or submission of medical records (Document drug, date,\nand duration of therapy) [e.g., adalimumab, Simponi (golimumab), Rinvoq\n(upadacitinib), Xeljanz/Xeljanz XR (tofacitinib), Enbrel (etanercept)].\n-AND-\n(c) History of failure, contraindication, or intolerance to three of the following\npreferred products (document drug, date, and duration of trial):\ni. One of the preferred adalimumab productsc\nii. Cimzia (certolizumab)\niii. Cosentyx (secukinumab)\niv. Enbrel (etanercept)\nv. Simponi (golimumab)\n-AND-\n(d) History of failure, contraindication, or intolerance to one of the following\n(document drug, date, and duration of trial):\ni. Xeljanz/Xeljanz XR (tofacitinib)\nii. Rinvoq (upadacitinib)\n-AND-\n(e) Patient is not receiving Taltz in combination with another targeted",
    " the following\n(document drug, date, and duration of trial):\ni. Xeljanz/Xeljanz XR (tofacitinib)\nii. Rinvoq (upadacitinib)\n-AND-\n(e) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nCosentyx (secukinumab), Simponi (golimumab), Orencia (abatacept),\nadalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\n© 2025 UnitedHealthcare Services Inc.\n5\n-AND-\n(f) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\nD. Non-radiographic Axial Spondyloarthritis\na. Taltz will be approved based on the following criteria:\n(1) Submission of medical records (e.g., chart notes, laboratory values) documenting\nall of the following:\n(a) Diagnosis of active non-radiographic axial spondyloarthritis\n-AND-\n(b) One of the following:\ni. History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date,\nand duration of trials)\n-OR-\nii. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of non-radiographic axial\nspondyloarthritis as documented by claims history or submission of\nmedical records (Document drug, date, and duration of therapy) [e.g.\nCimzia (certolizumab), Cosentyx (secukinumab), Rinvoq (upadacitinib)].\n-AND-\n(c) History of failure, contraindication, or intolerance to two of the following\npreferred products (document drug, date, and duration of trial):\ni. Cimzia (certolizumab)\nii. Cosentyx (secukinumab)\niii. Rinvoq (upadacitinib)\n-AND-\n(d) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nCosentyx (secukinumab), Simponi (golimumab), Orencia (abatacept),\nadalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\n-AND-\n© 20",
    "brel (etanercept), Cimzia (certolizumab),\nCosentyx (secukinumab), Simponi (golimumab), Orencia (abatacept),\nadalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n6\n(e) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\nc For a list of preferred products please reference drug coverage tools.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Exclusion: Taltz is excluded from coverage for the majority of our benefits\n• Supply limits may be in place.\n4. References:\n1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2022.\n2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the\ntreatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of\npsoriasis and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for\ntreatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of\npsoriasis with topical therapies. J Am Acad Dermatol 200",
    ". Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of\npsoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n7. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris –\nupdate 2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm\nVenereol 2015;29:2277-94.\n8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care\nfor the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the\ntreatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based\nconclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-74.\n9. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for\nthe management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann\nRheum Dis 2016;75:499-510.\n© 2025 UnitedHealthcare Services Inc.\n7\n10. Ward MM, Deodhar A, Dubreuil M, et al. 2019 update of the american college of\nrheumatology/spondylitis association of america/spondyloarthritis research and treatment\nnetwork recommendations for the treatment of ankylosing spondylitis and nonradiographic\naxial spondyloarthritis. Arthritis Rheumatol. 2019; Aug 22. doi: 10.1002/art.41042.\n11. Menter A, Strober BE, Kaplan DH et al. Joint AAD-NPF guidelines of care for the\nmanagement and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019:80:1029",
    "g 22. doi: 10.1002/art.41042.\n11. Menter A, Strober BE, Kaplan DH et al. Joint AAD-NPF guidelines of care for the\nmanagement and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019:80:1029-\n72.\nProgram Prior Authorization/Medical Necessity-Taltz (ixekizumab)\nChange Control\nDate Change\n8/2016 New Program.\n11/2016 Administrative change. Added California coverage information.\n5/2017 Updated disease severity criteria to include facial, genital area psoriasis,\ndecreased to 5% of body surface area. Added criteria for patients\nalready receiving Taltz. Updated references. Updated State Mandate\nReference\n2/2018 Updated background and added criteria for new indication of psoriatic\narthritis. Updated criteria adding Tremfya as additional preferred\noption for plaque psoriasis. Updated formatting without changes to\nclinical intent. Updated references.\n2/2019 Annual review. Updated background and criteria adding Cimzia to list\nof preferred products for the treatment of plaque psoriasis. Updated\nreference.\n9/2019 Updated background and criteria to include new indication for active\nankylosing spondylitis. Updated criteria for psoriasis and psoriatic\narthritis. Added coverage exclusion statement. Updated references.\n5/2020 Updated program to include new indication in pediatric patients with\nplaque psoriasis. Updated criteria for psoriatic arthritis and ankylosing\nspondylitis pertaining to nonbiologic therapies. Updated references.\n7/2020 Updated background and criteria to include new indication for non-\nradiographic axial spondyloarthritis. Clarified documentation\nrequirements. Updated references.\n11/2020 Added Tremfya as a step therapy medication for psoriatic arthritis.\nRevised formatting for psoriasis section to match other sections.\nModified psoriasis step requirement due to expanded indication for\nStelara.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD.\n12/2021 Updated the following with no change to clinical intent: updated\ncon",
    "e to expanded indication for\nStelara.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD.\n12/2021 Updated the following with no change to clinical intent: updated\nconventional DMARD bypass language for psoriatic arthritis and\npsoriasis, removed “biologic” from required preferred product criteria\nlanguage, updated age requirement language and updated CT/KY\nfootnote.\n3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.\n6/2022 Added Rinvoq and Xeljanz to step therapy medication for ankylosing\nspondylitis and Rinvoq to psoriatic arthritis. Added Rinvoq and/or\nXeljanz to examples where appropriate. Added Mississippi to state\nmandate footnote.\n© 2025 UnitedHealthcare Services Inc.\n8\n11/2022 Added Enbrel as a preferred product step option for PsO, PsA, and AS.\nAdded Enbrel as an example where appropriate. Added Rinvoq as a\nstep option for non-radiographic axial spondyloarthritis. Updated\nreference. Added targeted synthetic to DMARD bypass for non-\nradiographic axial spondyloarthritis.\n1/2023 Updated step therapy requirements to Humira or Amjevita. Updated\nlisted examples from Humira to adalimumab.\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\npreferred adalimumab products please reference drug coverage tools.”\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Updated step requirement noting Adalimumab-adaz (unbranded\nHyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab\nproducts with no change to clinical intent. Removed preferred\nadalimumab footnote. Added Sotyktu as step therapy agent for PsO.\nMoved Cosentyx to preferred step agent. Updated state mandate\nfootnote.\n4/2025 Removed examples for adalimumab in step therapy. Changed Stelara\nstep therapy to “One of the preferred ustekinumab productsc”. Changed\nStelara example to Ustekinumab. Added the fo",
    "ate\nfootnote.\n4/2025 Removed examples for adalimumab in step therapy. Changed Stelara\nstep therapy to “One of the preferred ustekinumab productsc”. Changed\nStelara example to Ustekinumab. Added the footnote “For a list of\npreferred products please reference drug coverage tools.”\n© 2025 UnitedHealthcare Services Inc.\n9"
  ]
}